Senseonics Holdings, Inc. has announced the FDA approval of its Eversense E3 CGM System. The company currently offers a 90-day capable continuous glucose monitor (CGM) but the Eversense E3 system will double that amount to 180 days. In addition, fewer fingerstick blood glucose measurements will be required.
https://www.notebookcheck.net/FDA-approves-Eversense-E3-6-month-continuous-glucose-monitor-that-requires-fewer-fingerstick-blood-glucose-measurements.599219.0.html